

# Raquel Largo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/729731/publications.pdf>

Version: 2024-02-01

144  
papers

5,190  
citations

81900

39  
h-index

91884

69  
g-index

149  
all docs

149  
docs citations

149  
times ranked

5772  
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR points to consider for minimal reporting requirements in synovial tissue research in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1640-1646.	0.9	12
2	Blocking chondrocyte hypertrophy in conditional <i>Evcc</i> knockout mice does not modify cartilage damage in osteoarthritis. <i>FASEB Journal</i> , 2022, 36, e22258.	0.5	5
3	6- <i>Shogaol</i> (enexasogol) treatment improves experimental knee osteoarthritis exerting a pleiotropic effect over immune innate signalling responses in chondrocytes. <i>British Journal of Pharmacology</i> , 2022, 179, 5089-5108.	5.4	8
4	Editorial: Inflammation and Biomarkers in Osteoarthritis. <i>Frontiers in Medicine</i> , 2021, 8, 727700.	2.6	7
5	Bone deleterious effects of different nrtis in treatment-naïve HIV patients after 12 and 48 weeks of treatment. <i>Current HIV Research</i> , 2021, 19, .	0.5	1
6	ATP transporters in the joints. <i>Purinergic Signalling</i> , 2021, 17, 591-605.	2.2	7
7	Joint obesity as a pathogenic factor in osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2021, 29, 1239-1241.	1.3	2
8	Response to: "Correspondence on "Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation?" by Angelides and Manolios. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrheumdis-2020-219721.	0.9	0
9	Criterion validity of ultrasound in the identification of calcium pyrophosphate crystal deposits at the knee: an OMERACT ultrasound study. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 261-267.	0.9	30
10	Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11490.	4.1	3
11	Treating osteoporotic osteoarthritis, or the art of cutting a balding man's hair. <i>Osteoarthritis and Cartilage</i> , 2020, 28, 239-241.	1.3	4
12	Modulation of the Inflammatory Process by Hypercholesterolemia in Osteoarthritis. <i>Frontiers in Medicine</i> , 2020, 7, 566250.	2.6	11
13	Setting up distinctive outcome measures for each osteoarthritis phenotype. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2093796.	2.7	13
14	Purinergic System Signaling in Metainflammation-Associated Osteoarthritis. <i>Frontiers in Medicine</i> , 2020, 7, 506.	2.6	13
15	Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1261-1263.	0.9	16
16	Disorganization of chondrocyte columns in the growth plate does not aggravate experimental osteoarthritis in mice. <i>Scientific Reports</i> , 2020, 10, 10745.	3.3	14
17	Adenosine Deaminase as a Biomarker of Tenofovir Mediated Inflammation in Naïve HIV Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3590.	4.1	4
18	OP0317 "ACCURACY OF THE OMERACT DEFINITIONS FOR IDENTIFICATION OF CALCIUM PYROPHOSPHATE CRYSTALS WITH ULTRASOUND: FINAL RESULTS OF THE OMERACT US IN CPPD SUB-TASK FORCE STUDY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 195.2-196.	0.9	0

#	ARTICLE	IF	CITATIONS
19	Chondrocyte enlargement is a marker of osteoarthritis severity. <i>Osteoarthritis and Cartilage</i> , 2019, 27, 1229-1234.	1.3	19
20	Inhibition of pSTAT1 by tofacitinib accounts for the early improvement of experimental chronic synovitis. <i>Journal of Inflammation</i> , 2019, 16, 2.	3.4	11
21	Recessive mutations in muscle-specific isoforms of FXR1 cause congenital multi-minicore myopathy. <i>Nature Communications</i> , 2019, 10, 797.	12.8	24
22	A subgroup of lupus patients with nephritis, innate T cell activation and low vitamin D is identified by the enhancement of circulating MHC class I-related chain A. <i>Clinical and Experimental Immunology</i> , 2019, 196, 336-344.	2.6	6
23	Targeting chronic innate inflammatory pathways, the main road to prevention of osteoarthritis progression. <i>Biochemical Pharmacology</i> , 2019, 165, 24-32.	4.4	72
24	FRIO529â€¦SPREAD OF SENESENCE AND JOINT INFLAMMATION VIA CONNEXIN43-POSITIVE EXOSOMES RELEASED BY OSTEOARTHRITIC CHONDROCYTES. , 2019, , .		1
25	Tenofovir Causes Bone Loss via Decreased Bone Formation and Increased Bone Resorption, Which Can Be Counteracted by Dipyridamole in Mice. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 923-938.	2.8	26
26	The ginger derivate 6-shogaol as a treatment in osteoarthritis. Modulation of chondrocyte hypertrophy and matrix calcification. <i>Osteoarthritis and Cartilage</i> , 2018, 26, S73-S74.	1.3	2
27	Parathyroid hormone-related protein exhibits antioxidant features in osteoblastic cells through its N-terminal and osteostatin domains. <i>Bone and Joint Research</i> , 2018, 7, 58-68.	3.6	23
28	Validation of Musculoskeletal Ultrasound in the Assessment of Experimental Gout Synovitis. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 1516-1524.	1.5	4
29	AB0102â€¦The ginger derivative 6-shogaol as a treatment in osteoarthritis.modulation of chondrocyte hypertrophy and matrix calcification. , 2018, , .		0
30	AB0094â€¦Possitive effetcs of chiropractic manipulation on subchondral bone mineral density, cartilage damage and synovial inflammation in osteoarthritic rabbits. , 2018, , .		0
31	Targeting of chondrocyte plasticity via connexin43 modulation attenuates cellular senescence and fosters a pro-regenerative environment in osteoarthritis. <i>Cell Death and Disease</i> , 2018, 9, 1166.	6.3	67
32	Mediators and Patterns of Muscle Loss in Chronic Systemic Inflammation. <i>Frontiers in Physiology</i> , 2018, 9, 409.	2.8	50
33	Changes in the size of hypertrophic chondrocytes in articular cartilage in osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2018, 26, S80-S81.	1.3	0
34	AB0075â€¦Intraarterial injection of human adipose-derived mesenchymal stem cells (HAD-MSCS) attenuates inflammation in acute arthritis model. , 2018, , .		0
35	Chondroitin sulfate â€” CONCEPT clear, uncertainties unchanged. <i>Nature Reviews Rheumatology</i> , 2017, 13, 576-577.	8.0	3
36	Unexpected Bone Formation Produced by RANKL Blockade. <i>Trends in Endocrinology and Metabolism</i> , 2017, 28, 695-704.	7.1	20

#	ARTICLE	IF	CITATIONS
37	Reply. Arthritis and Rheumatology, 2017, 69, 2093-2094.	5.6	0
38	Compensatory anabolic signaling in the sarcopenia of experimental chronic arthritis. Scientific Reports, 2017, 7, 6311.	3.3	23
39	FRI0071...Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis. , 2017, , .		0
40	Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis. British Journal of Pharmacology, 2017, 174, 3018-3031.	5.4	38
41	Combined Treatment With Chondroitin Sulfate and Glucosamine Sulfate Shows No Superiority Over Placebo for Reduction of Joint Pain and Functional Impairment in Patients With Knee Osteoarthritis: A Six-Month Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Arthritis and Rheumatology, 2017, 69, 77-85.	5.6	94
42	The combined therapy with chondroitin sulfate plus glucosamine sulfate or chondroitin sulfate plus glucosamine hydrochloride does not improve joint damage in an experimental model of knee osteoarthritis in rabbits. European Journal of Pharmacology, 2017, 794, 8-14.	3.5	21
43	OP0186...Tenofovir, a nucleoside analog reverse transcriptase inhibitor for treatment of hiv, promotes osteoclast differentiation and bone lost in vivo in a mechanism depending on atp release and adenosine, and dipyridamole may be a useful treatment to revert the effects. , 2017, , .		0
44	Increased synovial lipodystrophy induced by high fat diet aggravates synovitis in experimental osteoarthritis. Arthritis Research and Therapy, 2017, 19, 264.	3.5	44
45	OP0311...Synovial Lipodystrophy Induced by Hypercholesterolemia Aggravates Synovitis in An Experimental Model of Osteoarthritis in Rabbits. Annals of the Rheumatic Diseases, 2016, 75, 175.2-175.	0.9	0
46	The adipokine lipocalin-2 in the context of the osteoarthritic osteochondral junction. Scientific Reports, 2016, 6, 29243.	3.3	25
47	Muscle alterations in an experimental model of chronic arthritis. Osteoarthritis and Cartilage, 2016, 24, S345.	1.3	1
48	An update on the up and coming therapies to treat osteoarthritis, a multifaceted disease. Expert Opinion on Pharmacotherapy, 2016, 17, 1745-1756.	1.8	39
49	Synovial lipodystrophy induced by hypercholesterolemia aggravates synovitis in an experimental model of osteoarthritis in rabbits. Osteoarthritis and Cartilage, 2016, 24, S67.	1.3	0
50	Aromatase expression in human chondrocytes: An induction due to culture. Maturitas, 2016, 85, 27-33.	2.4	6
51	Chondroitin sulfate plus glucosamine sulfate does not show superiority over placebo in a randomised, double blind, placebo-controlled clinical trial in patients with knee osteoarthritis. Osteoarthritis and Cartilage, 2016, 24, S48-S49.	1.3	1
52	Oxidative stress, autophagy, epigenetic changes and regulation by miRNAs as potential therapeutic targets in osteoarthritis. Biochemical Pharmacology, 2016, 108, 1-10.	4.4	124
53	AB0137...Jak Inhibition by Tofacitinib Improves Rheumatoid Cachexia in a Rabbit Experimental Model That Reproduces the Lipid Paradox in Humans. Annals of the Rheumatic Diseases, 2015, 74, 936.3-937.	0.9	0
54	AB0106...The Small Gtpase Rhoa Signalling is Upregulated in the Cartilage of Patients with Knee Osteoarthritis Through the Phosphorylation of Myosin Light-Chain (MLC) Phosphatase Regulatory Unit MYPT-1 Induced by ERK: In Vivo and in Vitro Studies. Annals of the Rheumatic Diseases, 2015, 74, 926.1-926.	0.9	0

#	ARTICLE	IF	CITATIONS
55	AB0138â€¦Immunomodulatory Profile of Tofacitinib in the Treatment of Chronic Arthritis in Rabbits. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 937.1-937.	0.9	0
56	DXA in the assessment of subchondral bone mineral density in knee osteoarthritisâ€”A semi-standardized protocol after systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 275-283.	3.4	11
57	OP0077â€¦Muscle Alterations in an Experimental Model of Chronic Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 97.3-98.	0.9	0
58	Characterization of multinucleated giant cells in synovium and subchondral bone in knee osteoarthritis and rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 226.	1.9	61
59	TLR4 signalling in osteoarthritisâ€”finding targets for candidate DMOADs. <i>Nature Reviews Rheumatology</i> , 2015, 11, 159-170.	8.0	188
60	Osteoarthritis: a progressive disease with changing phenotypes. <i>Rheumatology</i> , 2014, 53, 1-3.	1.9	87
61	6â€”Shogaol inhibits chondrocytesâ€™ innate immune responses and cathepsinâ€”K activity. <i>Molecular Nutrition and Food Research</i> , 2014, 58, 256-266.	3.3	37
62	An OA phenotype may obtain major benefit from bone-acting agents. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 421-428.	3.4	31
63	The procatabolic cytokine interleukin-1 alfa induces a dysregulation of o-linked n-acetylglucosamine modified proteins in human osteoarthritic chondrocytes. <i>Osteoarthritis and Cartilage</i> , 2014, 22, S171-S172.	1.3	0
64	Is lecturing in Rheumatology Satellite Symposia a male attribute?. <i>Rheumatology International</i> , 2014, 34, 287-288.	3.0	7
65	Selective estrogen receptor modulators (SERMs): New alternatives for osteoarthritis?. <i>Maturitas</i> , 2014, 77, 380-384.	2.4	30
66	SDF-1 signaling: a promising target in rheumatic diseases. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 1077-1087.	3.4	50
67	O-linked N-acetylglucosamine (O-GlcNAc) protein modification is increased in the cartilage of patients with knee osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2014, 22, 259-263.	1.3	28
68	Biological role of the O-linked N-acetylglucosamine modified proteome in human osteoarthritic cartilage. <i>Osteoarthritis and Cartilage</i> , 2014, 22, S132.	1.3	0
69	CientÃ­ficos espaÃ±oles con los Dres. Greg Winter y Richard A. Lerner, premios PrÃ­ncipe de Asturias en InvestigaciÃ³n CientÃ­fica y TÃ©cnica 2012. <i>Inmunologia (Barcelona, Spain: 1987)</i> , 2013, 32, 70-74.	0.1	0
70	Lipid Transport and Metabolism in Healthy and Osteoarthritic Cartilage. <i>International Journal of Molecular Sciences</i> , 2013, 14, 20793-20808.	4.1	89
71	FRI0040â€¦Transitional zones displacement of the subchondral bone layers in a model of osteoporosis and osteoarthritis in rabbits. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A381.2-A381.	0.9	0
72	Visfatin: a new player in rheumatic diseases. <i>Immunometabolism</i> , 2013, 1, .	6.0	1

#	ARTICLE	IF	CITATIONS
73	Hypercholesterolemia boosts joint destruction in chronic arthritis. An experimental model aggravated by foam macrophage infiltration. <i>Arthritis Research and Therapy</i> , 2013, 15, R81.	3.5	27
74	O-Glcnac protein modification stimulates chondrogenesis in vitro and chondrocyte hypertrophy in mouse. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A71.1-A71.	0.9	0
75	RANKL produced by articular chondrocytes contributes to juxta-articular bone loss in chronic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A68.3-A69.	0.9	1
76	6-Shogaol inhibits cathepsin-K activity and has anticatabolic and anti-inflammatory properties in stimulated chondrocytes. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A68.2-A68.	0.9	0
77	Subchondral bone remodelling and osteoarthritis. <i>Arthritis Research and Therapy</i> , 2012, 14, .	3.5	3
78	The Increase in O-Linked N-Acetylglucosamine Protein Modification Stimulates Chondrogenic Differentiation Both in Vitro and in Vivo. <i>Journal of Biological Chemistry</i> , 2012, 287, 33615-33628.	3.4	80
79	Does RANKL produced by articular chondrocytes actively participate in juxta-articular bone loss related to chronic arthritis?. <i>Bone</i> , 2012, 50, S97.	2.9	0
80	Anti-inflammatory and anti-resorptive properties of ginger derivatives. <i>Bone</i> , 2012, 50, S99.	2.9	0
81	Effects of PTH [1-34] on synoviopathy in an experimental model of osteoarthritis preceded by osteoporosis. <i>Osteoarthritis and Cartilage</i> , 2012, 20, 1619-1630.	1.3	22
82	RANKL synthesized by articular chondrocytes contributes to juxta-articular bone loss in chronic arthritis. <i>Arthritis Research and Therapy</i> , 2012, 14, R149.	3.5	49
83	Subchondral bone as a key target for osteoarthritis treatment. <i>Biochemical Pharmacology</i> , 2012, 83, 315-323.	4.4	220
84	Rankl produced by articular chondrocytes induces bone loss associated with arthropathies. <i>Osteoarthritis and Cartilage</i> , 2012, 20, S65-S66.	1.3	0
85	Identification of an extracellular o-n-acetyl-glycosylase responsible for an increased level of O-linked n-acetylglucosamine modified proteins in the cartilage of patients with osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2012, 20, S118.	1.3	0
86	Study of the O-linked-N-acetyl-glucosaminylation of proteins induced by high doses of glucosamine and its correlation with osteoarthritis progression. <i>Osteoarthritis and Cartilage</i> , 2012, 20, S126.	1.3	2
87	Functional estrogen biosynthesis machinery is expressed in human postmenopausal osteoarthritis chondrocytes. <i>Osteoarthritis and Cartilage</i> , 2012, 20, S141.	1.3	0
88	O-GlcNAc protein modification stimulates chondrogenesis in vitro and chondrocyte hypertrophy in mouse. <i>Osteoarthritis and Cartilage</i> , 2012, 20, S150.	1.3	0
89	Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. <i>Osteoarthritis and Cartilage</i> , 2011, 19, 1228-1236.	1.3	98
90	Bone mineral density and joint cartilage: four clinical settings of a complex relationship in osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1523-1525.	0.9	47

#	ARTICLE	IF	CITATIONS
91	Effects of CTLA4-Ig on monocyte/macrophage differentiation and cytokine production. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A68-A69.	0.9	0
92	Glucosamine sulfate for knee osteoarthritis: science and evidence-based use. <i>Therapy: Open Access in Clinical Medicine</i> , 2010, 7, 591-604.	0.2	4
93	089 PTH IMPROVES SYNOVITIS IN AN EXPERIMENTAL MODEL OF OSTEOARTHRITIS PRECEDED BY OSTEOPOROSIS. <i>Osteoarthritis and Cartilage</i> , 2010, 18, S47.	1.3	0
94	244 OSTEOARTHRITIS LEADS TO INCREASED LEVELS OF PROTEIN O-LINKED N-ACETYLGLUCOSAMINE IN THE CARTILAGE. <i>Osteoarthritis and Cartilage</i> , 2010, 18, S111-S112.	1.3	2
95	Improvement of experimental accelerated atherosclerosis by chondroitin sulphate. <i>Osteoarthritis and Cartilage</i> , 2010, 18, S12-S16.	1.3	8
96	Chondroitin sulfate improves synovitis in rabbits with chronic antigen-induced arthritis. <i>Osteoarthritis and Cartilage</i> , 2010, 18, S17-S23.	1.3	18
97	Nonsteroidal antiinflammatory drugs and prostaglandin E <sub>2</sub> modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 478-488.	6.7	42
98	Effects of estrogen deficiency and low bone mineral density on healthy knee cartilage in rabbits. <i>Journal of Orthopaedic Research</i> , 2010, 28, 812-818.	2.3	26
99	Pharmacological modulation by celecoxib of cachexia associated with experimental arthritis and atherosclerosis in rabbits. <i>British Journal of Pharmacology</i> , 2010, 161, 1012-1022.	5.4	14
100	PTH Increases Jaw Mineral Density in a Rabbit Model of Osteoporosis. <i>Journal of Dental Research</i> , 2010, 89, 360-365.	5.2	27
101	Subchondral bone microstructural damage by increased remodelling aggravates experimental osteoarthritis preceded by osteoporosis. <i>Arthritis Research and Therapy</i> , 2010, 12, R152.	3.5	180
102	Effect of a high dose of glucosamine on systemic and tissue inflammation in an experimental model of atherosclerosis aggravated by chronic arthritis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009, 297, H268-H276.	3.2	49
103	Differential effects of the antioxidant n-acetylcysteine on the production of catabolic mediators in IL-1 $\beta$ -stimulated human osteoarthritic synoviocytes and chondrocytes. <i>European Journal of Pharmacology</i> , 2009, 623, 125-131.	3.5	32
104	Osteoarthritis associated with estrogen deficiency. <i>Arthritis Research and Therapy</i> , 2009, 11, 241.	3.5	236
105	Characterization of a new experimental model of osteoporosis in rabbits. <i>Journal of Bone and Mineral Metabolism</i> , 2008, 26, 53-59.	2.7	99
106	Does oral glucosamine prevent subchondral bone loss in an animal model of osteoarthritis? Comment on the article by Wang et al. <i>Arthritis and Rheumatism</i> , 2008, 58, 635-635.	6.7	5
107	Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 1264-1274.	6.7	85
108	Chronic arthritis aggravates vascular lesions in rabbits with atherosclerosis: A novel model of atherosclerosis associated with chronic inflammation. <i>Arthritis and Rheumatism</i> , 2008, 58, 2723-2734.	6.7	26



#	ARTICLE	IF	CITATIONS
109	Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis. <i>British Journal of Pharmacology</i> , 2008, 154, 843-851.	5.4	47
110	Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2008, 16, 1484-1493.	1.3	43
111	Diacerein has a weak effect on the catabolic pathway of human osteoarthritis synovial fibroblast-comparison to its effects on osteoarthritic chondrocytes. <i>Rheumatology</i> , 2008, 47, 627-633.	1.9	32
112	The reverse glucosamine sulfate pathway: application in knee osteoarthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 215-225.	1.8	8
113	Osteoporosis increases the severity of cartilage damage in an experimental model of osteoarthritis in rabbits. <i>Osteoarthritis and Cartilage</i> , 2007, 15, 69-77.	1.3	102
114	Prostaglandin E2 receptors EP1 and EP4 are up-regulated in rabbit chondrocytes by IL-1 $\beta$ , but not by TNF $\alpha$ . <i>Rheumatology International</i> , 2007, 27, 911-917.	3.0	16
115	Bone mineral measurements of subchondral and trabecular bone in healthy and osteoporotic rabbits. <i>Skeletal Radiology</i> , 2006, 35, 34-41.	2.0	118
116	Expression of the peptide C4b-binding protein A in the arthritic joint. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1279-1285.	0.9	8
117	Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 998-1005.	0.9	70
118	Sequential changes of parathyroid hormone related protein (PTHrP) in articular cartilage during progression of inflammatory and degenerative arthritis. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 917-922.	0.9	18
119	EP2/EP4 signalling inhibits monocyte chemoattractant protein-1 production induced by interleukin 1 $\alpha$ in synovial fibroblasts. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1197-1204.	0.9	40
120	Tight blood pressure control decreases apoptosis during renal damage. <i>Kidney International</i> , 2004, 65, 811-822.	5.2	13
121	Histopathological correlation of cartilage swelling detected by magnetic resonance imaging in early experimental osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2004, 12, 878-886.	1.3	120
122	Glucosamine inhibits IL-1 $\beta$ -induced NF $\kappa$ B activation in human osteoarthritic chondrocytes. <i>Osteoarthritis and Cartilage</i> , 2003, 11, 290-298.	1.3	341
123	A fibrin based model for rheumatoid synovitis. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 1135-1138.	0.9	45
124	Fibrin generated in the synovial fluid activates intimal cells from their apical surface: a sequential morphological study in antigen-induced arthritis. <i>British Journal of Rheumatology</i> , 2003, 42, 19-25.	2.3	28
125	Modulation of cell recruitment by anti-inflammatory agents in antigen-induced arthritis. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 1027-1030.	0.9	32
126	Studies of Piroxicam Absorption by Oral Mucosa. <i>Arzneimittelforschung</i> , 2002, 52, 385-387.	0.4	4



#	ARTICLE	IF	CITATIONS
127	Short-term and long-term variability of standard deviation scores for size in children. <i>Annals of Human Biology</i> , 2002, 29, 202-218.	1.0	15
128	Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. <i>American Journal of Physiology - Renal Physiology</i> , 2001, 281, F38-F47.	2.7	155
129	Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. <i>Kidney International</i> , 2001, 59, 2222-2232.	5.2	213
130	Up-regulation of parathyroid hormone-related protein in folic acid-induced acute renal failure. <i>Kidney International</i> , 2001, 60, 982-995.	5.2	28
131	Activation of NF- $\kappa$ B in Tubular Epithelial Cells of Rats With Intense Proteinuria. <i>Hypertension</i> , 2001, 37, 1171-1178.	2.7	155
132	Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. <i>Kidney International</i> , 2001, 59, 2222.	5.2	22
133	Angiotensin-Converting Enzyme Is Upregulated in the Proximal Tubules of Rats With Intense Proteinuria. <i>Hypertension</i> , 1999, 33, 732-739.	2.7	98
134	Renal expression of parathyroid hormone-related protein (PTHrP) and PTH/PTHrP receptor in a rat model of tubulointerstitial damage. <i>Kidney International</i> , 1999, 55, 82-90.	5.2	48
135	Endothelin-1 Expression During Early Response After Antigen Challenge in Brown "Norway Rats. <i>Pulmonary Pharmacology and Therapeutics</i> , 1998, 11, 215-219.	2.6	5
136	Endothelin-1 Upregulation in the Kidney of Uninephrectomized Spontaneously Hypertensive Rats and Its Modification by the Angiotensin-Converting Enzyme Inhibitor Quinapril. <i>Hypertension</i> , 1997, 29, 1178-1185.	2.7	29
137	Quinapril decreases renal endothelin-1 expression and synthesis in a normotensive model of immune-complex nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 1997, 8, 756-768.	6.1	23
138	Platelet-activating factor stimulates gene expression and synthesis of matrix proteins in cultured rat and human mesangial cells: role of TGF-beta. <i>Journal of the American Society of Nephrology: JASN</i> , 1997, 8, 1266-1275.	6.1	21
139	Glomerular up-regulation of EIIIA and V120 fibronectin isoforms in proliferative immune complex nephritis. <i>Kidney International</i> , 1996, 50, 908-919.	5.2	13
140	An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis. <i>Kidney International</i> , 1996, 50, 962-972.	5.2	67
141	Effects and Interactions of Endothelin-1 and Angiotensin II on Matrix Protein Expression and Synthesis and Mesangial Cell Growth. <i>Hypertension</i> , 1996, 27, 885-892.	2.7	138
142	ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. <i>Kidney International</i> , 1995, 48, 1778-1791.	5.2	113
143	Measures of body mass and of obesity from infancy to adulthood and their appropriate transformation. <i>Annals of Human Biology</i> , 1994, 21, 111-125.	1.0	44
144	Multinucleated giant cells in synovia from people with rheumatoid arthritis or osteoarthritis. <i>Bone Abstracts</i> , 0, , .	0.0	0